Radioligand therapy for selected prostate cancer and neuroendocrine tumor patients.
Request Medical OpinionAdvanced treatment information for international patients and healthcare professionals.
Lu-177 PSMA may be used in selected metastatic prostate cancer cases after PSMA PET/CT evaluation.
Lu-177 DOTA may be used in selected neuroendocrine tumors after DOTA PET/CT evaluation.
Eligibility depends on tumor type, PET uptake, organ function, blood counts and performance status.
Treatment is usually planned in cycles according to specialist decision.
Blood tests, renal function, tumor markers and imaging may be used during follow-up.
Targeted treatment approach for selected patients with appropriate uptake.
PET/CT, pathology, laboratory tests and previous treatment records are usually required.
Final protocol and pricing require complete medical evaluation.
Patients should submit medical reports, imaging files, pathology results, previous treatment history and current clinical information.
Our team organizes the case and coordinates specialist evaluation before treatment planning, estimated duration and quotation.
Submit Your ReportsTreatment suitability, protocol, number of sessions, hospital stay and cost depend on diagnosis, disease stage, previous treatments and specialist evaluation.
Send your reports and receive professional treatment planning support.